Program
N-Methyl-3,4-methylenedioxyamphetamine
Also written as “Midomafetamine HCl”, “Midomafetamine” and “midomafetamine HCl”.
Its studies are mostly in Stress Disorders, Post-Traumatic · Autism Spectrum Disorder · Autistic Disorder · Anxiety Disorders · Binge-Eating Disorder, led by 4 companies.
Drug pageN-Methyl-3,4-methylenedioxyamphetamine: every studyAll 91 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Resilient Pharmaceuticalsits history only | 262 open or running | phase 3since May 14, 2018 | Aug 24, 2004 | Dec 2028phase 1 · NCT03606538 |
| Definium Therapeutics USits history only | 10 open or running | phase 2since Dec 22, 2025 | Dec 22, 2025 | none ahead |
| MAPS Europe | 10 open or running | phase 2since Jul 19, 2019 | Jul 19, 2019 | none ahead |
| Remedyits history only | 10 open or running | phase 2since Sep 19, 2021 | Sep 19, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of MAPS Europe only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 19, 2019First study: phase 2 study in Stress Disorders, Post-TraumaticFirst studyNCT04030169 · 21 enrolled · Czechia, Germany, Netherlands and more
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study MAPS Europe leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04030169Stress Disorders, Post-Traumatic · Czechia, Germany, Netherlands and more | 2 | Completed | Dec 14, 2023 | 21 |
How it is read
Names in the registry
- “Midomafetamine HCl”, 10 entries
- “Midomafetamine”, 7 entries
- “midomafetamine HCl”, 2 entries
- “MDMA”, 2 entries
- “midomafetamine”, 2 entries
Conditions, from the studies’ own filings
- Stress Disorders, Post-Traumatic, 19 studies
- Autism Spectrum Disorder, 1 study
- Autistic Disorder, 1 study
- Anxiety Disorders, 1 study
- Binge-Eating Disorder, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.